Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
32.06 CHF | +0.68% | +1.90% | +18.70% |
07/06 | AbbVie's tight grip on Humira market raises concerns about biosimilars | RE |
22/05 | Sandoz: Marketing authorization for Wyost and Jubbonti in the EU | CF |
Business Summary
Number of employees: 22,633
Sales per Business
CHF in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Generics
77.0
%
| 6,820 | 78.7 % | 6,679 | 77.0 % | -2.07% |
Biosimilars
23.0
%
| 1,841 | 21.3 % | 1,991 | 23.0 % | +8.10% |
Sales per region
CHF in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Europe
35.5
%
| 1,932 | 22.3 % | 3,073 | 35.5 % | +59.07% |
International
25.9
%
| 2,361 | 27.3 % | 2,242 | 25.9 % | -5.03% |
United States
16.8
%
| 1,565 | 18.1 % | 1,453 | 16.8 % | -7.17% |
Germany
12.9
%
| 1,121 | 12.9 % | 1,114 | 12.9 % | -0.62% |
North America
5.3
%
| - | - | 460 | 5.3 % | - |
Switzerland
3.8
%
| 275 | 3.2 % | 326 | 3.8 % | +18.60% |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 431,000,000 | 393,474,532 ( 91.29 %) | 1,070,754 ( 0.2484 %) | 91.29 % |
Company contact information
Sector
Sales per Business
Sales per region
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+18.66% | 15.34B | |
+20.76% | 43.54B | |
+18.62% | 21.51B | |
+26.37% | 15.12B | |
+56.64% | 13.37B | |
-0.05% | 6.79B | |
-14.94% | 6.38B | |
-8.87% | 5.73B | |
+8.17% | 5.36B | |
+27.27% | 4.63B |
- Stock Market
- Equities
- SDZ Stock
- Company Sandoz Group AG